Skip to main content
. 2021 Feb 4;11:3079. doi: 10.1038/s41598-021-82750-y

Table 3.

Univariable and multivariable Cox proportional hazard model of overall survival (OS) and cancer-specific survival (CSS) in five pTN groups.

OS (n = 4236, event = 351) CSS (n = 4236, event = 212)
Univariable model Multivariable model Univariable model Multivariable model
HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value HR (95% CI) p value
Group pT1N0 1 (ref) 1 (ref) 1 (ref) 1 (ref)
pTxN1 8.78 (5.58–13.83) < .001 5.86 (3.41–10.06) < .001 15.22 (8.87–26.12) < .001 9.34 (5.01–17.41) < .001
pT2N0 1.77 (1.26–2.49) 0.001 1.15 (0.80–1.66) 0.457 3.24 (2.13–4.94) < .001 2.13 (1.35–3.36) 0.001
pT3N0 4.13 (3.23–5.29) < .001 2.14 (1.61–2.83) < .001 7.53 (5.48–10.34) < .001 4.12 (2.90–5.87) < .001
pT4N0 11.46 (6.05–21.69) < .001 4.89 (2.39–9.99) < .001 25.24 (13.04–48.86) < .001 10.33 (4.93–21.63) < .001
Age at operation 1.05 (1.04–1.06) < .001 1.03 (1.02–1.04) < .001 1.03 (1.02–1.04) < .001 1.02 (1.00–1.03) 0.032
Body mass index (kg/cm2) 0.92 (0.88–0.95) < .001 0.93 (0.89–0.96) < .001 0.90 (0.86–0.94) < .001 0.91 (0.86–0.95) < .001
Diabetes Yes 1.89 (1.46–2.45) < .001 1.75 (1.31–2.33) < .001 1.82 (1.31–2.54) < .001 2.21 (1.53–3.18) < .001
Hypertension Yes 1.43 (1.15–1.78) 0.001 1.35 (1.04–1.75) 0.023 1.32 (0.99–1.74) 0.055
ASA 1 + 2 1 (ref) 1 (ref) 1 (ref) 1 (ref)
3 + 4 4.23 (3.01–5.94) < .001 3.08 (2.15–4.41) < .001 3.27 (2.01–5.31) < .001 2.37 (1.41–3.96) 0.001
Hb Female (≤ 12), male (≤ 13) 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Female (> 12), male (> 13) 0.27 (0.21–0.34) < .001 0.50 (0.39–0.64) < .001 0.25 (0.19–0.33) < .001 0.53 (0.39–0.74) < .001
Platelet ≥ 150, ≤ 450 1 (ref) 1 (ref)
< 150 1.33 (0.82–2.15) 0.253 0.67 (0.30–1.53) 0.343
> 450 3.61 (1.91–6.82) < .001 3.85 (1.80–8.24) 0.001
Creatinine ≤ 1.3 1 (ref) 1 (ref)
> 1.3 2.44 (1.81–3.31) < .001 2.56 (1.75–3.76) < .001
Albumin ≤ 3.0 1 (ref) 1 (ref)
> 3.0 0.27 (0.15–0.47) < .001 0.22 (0.12–0.42) < .001
Nephrectomy Open surgery 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Laparoscopic 0.32 (0.24–0.41) < .001 0.61 (0.45–0.83) 0.002 0.30 (0.21–0.42) < .001 0.63 (0.43–0.93) 0.019
Operative extent Partial 1 (ref) 1 (ref) 1 (ref)
Radical 2.76 (1.95–3.91) < .001 1.51 (1.03–2.22) 0.036 4.18 (2.51–6.97) < .001
Histology Clear cell 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Non-clear cell 0.91 (0.65–1.28) 0.579 0.89 (0.62–1.28) 0.535 0.99 (0.65–1.51) 0.976 0.94 (0.60–1.46) 0.782
Mixed 3.32 (1.64–6.70) 0.001 2.21 (0.99–4.94) 0.054 4.66 (2.19–9.95) < .001 2.93 (1.25–6.90) 0.014
Nuclear grade Grade 1–2 1 (ref) 1 (ref) 1 (ref) 1 (ref)
Grade 3–4 2.32 (1.78–3.04) < .001 1.73 (1.29–2.32) < .001 3.83 (2.64–5.56) < .001 2.68 (1.78–4.04) < .001
Sarcomatoid differentiation Yes 3.85 (2.25–6.58) < .001 1.98 (1.09–3.60) 0.026 5.73 (3.26–10.07) < .001 1.85 (0.97–3.52) 0.063
Necrosis Yes 1.80 (1.30–2.51) 0.001 2.70 (1.88–3.89) < .001
Lymphovascular invasion Yes 2.64 (1.85–3.76) < .001 3.56 (2.37–5.34) < .001
Capsular invasion Yes 1.02 (0.78–1.33) 0.877 1.25 (0.90–1.73) 0.185